Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved Drugs
The Food and Drug Administration approved five new Novartis (NYSE: NVS) drugs last year, the most of any big pharma in 2019. Moreover, those compounds address five different disease areas, offering the company opportunities to tackle a variety of markets.
Given its a history of positive earnings surprises, its reasonable valuation, and Wall Street's strong buy rating on its stock, the potential revenue from those new drugs is just one more reason to be optimistic about Novartis shares this year.
Image source: Getty Images.
Source Fool.com
